Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph plus lymphoid blast crisis of chronic myeloid leukaemia

被引：6

作者：

Breccia, Massimo ^{[1
]}

Serrao, Alessandra ^{[1
]}

Salaroli, Adriano ^{[1
]}

Loglisci, Giuseppina ^{[1
]}

Zacheo, Irene ^{[1
]}

Alimena, Giuliana ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Haematol, Rome, Italy

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷 / 05期

关键词：

chronic myeloid leukaemia; lymphoid blast crisis; dasatinib; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; IMATINIB-RESISTANT; EFFICACY; TRANSFORMATION; MESYLATE; PHASE;

D O I：

10.1111/bjh.12079

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：612 / 613

页数：2

共 8 条

[1] Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy [J].

Alimena, Giuliana ;

Breccia, Massimo ;

Latagliata, Roberto ;

Carmosino, Ida ;

Russo, Eleonora ;

Biondo, Francesca ;

Diverio, Daniela ;

Mancini, Marco ;

Nanni, Mauro ;

Mandelli, Franco .

CANCER, 2006, 107 (05) :1008-1013

[2] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase [J].

Cortes, J. ;

Kim, D-W ;

Raffoux, E. ;

Martinelli, G. ;

Ritchie, E. ;

Roy, L. ;

Coutre, S. ;

Corm, S. ;

Hamerschlak, N. ;

Tang, J-L ;

Hochhaus, A. ;

Khoury, H. J. ;

Bruemmendorf, T. H. ;

Michallet, M. ;

Rege-Cambrin, G. ;

Gambacorti-Passerini, C. ;

Radich, J. P. ;

Ernst, T. ;

Zhu, C. ;

Van Tornout, J. M. A. ;

Talpaz, M. .

LEUKEMIA, 2008, 22 (12) :2176-2183

[3] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[4] Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate [J].

Jabbour, E ;

Kantarjian, H ;

O'Brien, S ;

Rios, MB ;

Abruzzo, L ;

Verstovsek, S ;

Garcia-Manero, G ;

Cortes, J .

BLOOD, 2006, 107 (02) :480-482

[5] Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation [J].

Milojkovic, Dragana ;

Ibrahim, Amr ;

Reid, Alistair ;

Foroni, Letizia ;

Apperley, Jane ;

Marin, David .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03) :473-474

[6] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia [J].

Rea, D ;

Legros, L ;

Raffoux, E ;

Thomas, X ;

Turlure, P ;

Maury, S ;

Dupriez, B ;

Pigneux, A ;

Choufi, B ;

Reman, O ;

Stéphane, D ;

Royer, B ;

Vigier, M ;

Ojeda-Uribe, M ;

Recher, C ;

Dombret, H ;

Huguet, F ;

Rousselot, P .

LEUKEMIA, 2006, 20 (03) :400-403

[7] Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia in Blast Phase After 2 Years of Follow-Up in a Phase 3 Study Efficacy and Tolerability of 140 Milligrams Once Daily and 70 Milligrams Twice Daily [J].

Saglio, Giuseppe ;

Hochhaus, Andreas ;

Goh, Yeow Tee ;

Masszi, Tamas ;

Pasquini, Ricardo ;

Maloisel, Frederic ;

Erben, Philipp ;

Cortes, Jorge ;

Paquette, Ronald ;

Bradley-Garelik, M. Brigid ;

Zhu, Chao ;

Dombret, Herve .

CANCER, 2010, 116 (16) :3852-3861

[8]

Shah Neil P, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS31

← 1 →